Myeloma

IMF Launches World’s First DNA Database for Myeloma Patients

A biologist at Washington University in St. Louis has shown that for some fish species, females prefer males with larger sexual organs, and actually choose them for mating. That does not exclude males with an average-sized sex organ, called a gonopodium. These fish out-compete the larger-endowed males in a predator-laden environment because they have a faster burst speed than the males with large...

Compound from marine bacteria shows potential as multiple myeloma therapy

An anti-cancer compound derived from bacteria dwelling in ocean-bottom sediments appears in laboratory tests to be a potent killer of drug-resistant multiple myeloma cells, and potentially with less toxicity than current treatments, report Dana-Farber Cancer Institute researchers in the November issue of Cancer Cell. The experimental compound, NPI-0052, has been found to block or inhibit c...

Genome changes tracked during multiple myeloma initiation, progression and treatment

Scientists have made significant progress toward elucidating key genetic events associated with the development and progression of multiple myeloma (MM), an incurable malignancy that is the second most common cancer of the blood. The results, published in the April issue of Cancer Cell, provide new genetic and biological insights that open innovative directions for the discovery of effective ther...

An advanced genetic diagnostic method for multiple myeloma

A researcher at the University of Navarra, Borja Sáez Ochoa, has proposed a new genetic diagnostic method for multiple myeloma (MM), a type of bone marrow cancer, which permits the detection of this disease in earlier stages. The dissertation of this biologist, produced in the Department of Genetics of the School of Sciences of the University of Navarra, and in the Institute of Human Genet...

Investigating the measles virus as a tool to kill multiple myeloma

Mayo Clinic Cancer Center has opened a new Phase I clinical trial testing an engineered measles virus against multiple myeloma, a cancer of the bone marrow that currently has no cure. This is the third of a series of molecular medicine studies in patients testing the potential of measles to kill cancer. “This is the beginning of a long but exciting process,?says Angela Dispenzieri, M.D.,...

Myeloma at Biology Products

No data found

Search Myeloma biology products at Google

Search Myeloma biology products at Yahoo

Search Myeloma biology products at Msn

Myeloma at Biology Technology

No data found

Search Myeloma biology technology at Google

Search Myeloma biology technology at Yahoo

Search Myeloma biology technology at Msn

Myeloma at Medicine News

Associated therapy for multiple myeloma

According to a new study it is observed that thalidomide is effective as first-line therapy for newly diagnosed multiple myeloma patients when combined with a standard chemotherapy agent. Researchers from the Mayo Clinic in Rochester, Minn.// gave 60 newly diagnosed myeloma patients the drug thalidomide along with the synthetic steroid dexamethasone. Results show 55 percent of patients responded...

Latest drug shows promise in multiple myeloma

According to researchers, many trials show that a new type of drug can assist patients with multiple myeloma who have failed to respond to other treatments.// Multiple myeloma is an incurable cancer of the bone marrow. Researchers at Dana-Farber Cancer Institute have been assessing a new drug, called bortezomib, in a group of 180 patients who had not been helped by other forms of treatment. In th...

Bortezomib for salvage therapy against progressive myeloma

Despite the initial efficacy of these therapies against multiple myeloma (MM), relapse is invariably the rule. Bortezomib (Velcade, formerly PS-341, Millennium, USA) is a novel first-class agent that inhibits the proteasome, a // multicatalytic cellular enzyme whose activity entails several molecular mechanisms, including, in particular, the NF-kB pathway. Currently, bortezomib, alon...

Plasma Exchange Of No Use In Multiple Myeloma

New findings published in the Annals of Internal Medicine this week have found that the standard therapy for patients who are on the verge of kidney failure is useless. //The study conducted by researchers at Lawson Health Research Institute scientists in London, Canada found that a treatment called "plasma exchange" in patients with multiple myeloma has no benefits. This means that the...

Lenalidomide, Granted Approval by FDA to Join Multiple Myeloma Drugs

Graham Burton, M.D., SVP, Regulatory Affairs and Pharmacovigilance said that FDA’s approval of REVLIMID (lenalidomide) offered a new oral drug option// to the group of people suffering from multiple myeloma. Celgene Corporation (Nasdaq: CELG) announced that the U.S. Food and Drug Administration (FDA) has granted approval for its Supplemental New Drug Application (sNDA) for an additional...

More>>

Myeloma at Medicine Products

Chromosome Analysis, Multiple Myeloma Panel by FISH

Description:ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, maj...
Company:ARUP Laboratories

Multiple Myeloma Panel by FISH

Description:ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, maj...
Company:ARUP Laboratories

Myeloma at Medicine Technology

Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia

Data presented at the 11th International Myeloma Workshop held inKos, Greece demonstrates clinical activity of perifosine incombination with bortezomib, dexamethasone and lenalidomide plusdexamethasone, in patients with relapsed/refractory multiplemyeloma, and as a single agent in patients with relapsed/refractoryWaldenstrom's macroglobulinemia NEW YORK, June 29, 2007 /PRNewswire-FirstCal...

The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece

BRUSSELS, Belgium and KOS, Greece, June 29, 2007 /PRNewswire/ --The European Myeloma Platform (EMP) says updated data forpreviously treated patients on REVLIMID (lenalidomide) plus thesteroid dexamethasone shows median survival of 35 months, nearlythree years. The data are pooled from two large randomizedcontrolled Phase III trials that enrolled more than 700 patientsfrom nearly 100 clin...

The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients

- Data Presented at the 11th International Myeloma Workshop - NORTH HOLLYWOOD, Calif., and KOS, Greece, June 29, 2007/PRNewswire/ -- The International Myeloma Foundation (IMF) --supporting research and providing education, advocacy and supportfor myeloma patients, families, researchers and physicians -- todaysaid that updated statistics reported at the 11th InternationalMyeloma Workshop i...

Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma

- 100 percent of patients treated with VELCADE, cyclophosphamide,and prednisone alive at one year - KOS, Greece, June 28, 2007 /PRNewswire-FirstCall/ -- MillenniumPharmaceuticals, Inc. today reported on the presentation of resultsfrom clinical trials of VELCADE based therapies that showed highcomplete remission / complete response(1) (CR) rates in previouslytreated multiple myeloma (MM) p...

Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients

-- 100 percent response rate achieved with VELCADE, lenalidomideand dexamethasone KOS, Greece, June 28 /PRNewswire-FirstCall/ -- MillenniumPharmaceuticals, Inc. (Nasdaq: MLNM) today reported on thepresentation of results from four clinical trials of VELCADE basedtherapies that showed consistently high survival and completeremission / complete response(1) (CR) rates in newly diag...

More>>

Myeloma at Medicine Dictionary

Myeloma

Common Misspellings: mygloma Search All o...

Multiple myeloma

<A href="http:/ / www.mayoclinic.com/ health/ multiple-mye...